Relay Therapeutics Inc (NASDAQ: RLAY) on Friday, soared 3.64% from the previous trading day, before settling in for the closing price of $5.64. Within the past 52 weeks, RLAY’s price has moved between $5.60 and $12.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 319.82% over the past five years. The company achieved an average annual earnings per share of -2.18%. With a float of $120.68 million, this company’s outstanding shares have now reached $127.46 million.
Let’s look at the performance matrix of the company that is accounted for 323 employees. In terms of profitability, gross margin is 84.38%, operating margin of -1051.18%, and the pretax margin is -916.92%.
Relay Therapeutics Inc (RLAY) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Relay Therapeutics Inc is 25.73%, while institutional ownership is 55.86%. The most recent insider transaction that took place on Oct 28 ’24, was worth 9,823. In this transaction an insider of this company sold 1,621 shares at a rate of $6.06, taking the stock ownership to the 390,063 shares. Before that another transaction happened on Oct 28 ’24, when Company’s Chief Financial Officer sold 6,802 for $6.06, making the entire transaction worth $41,220. This insider now owns 306,391 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -2.18% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Relay Therapeutics Inc (RLAY) is currently performing well based on its current performance indicators. A quick ratio of 15.64 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.52, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach -3.14 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Relay Therapeutics Inc (NASDAQ: RLAY) saw its 5-day average volume 1.4 million, a negative change from its year-to-date volume of 1.45 million. As of the previous 9 days, the stock’s Stochastic %D was 8.77%. Additionally, its Average True Range was 0.40.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 4.69%, which indicates a significant decrease from 17.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.53% in the past 14 days, which was lower than the 94.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.88, while its 200-day Moving Average is $7.60. Nevertheless, the first resistance level for the watch stands at $6.02 in the near term. At $6.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.39. If the price goes on to break the first support level at $5.65, it is likely to go to the next support level at $5.45. Assuming the price breaks the second support level, the third support level stands at $5.28.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
Market capitalization of the company is 983.29 million based on 133,890K outstanding shares. Right now, sales total 25,550 K and income totals -341,970 K. The company made 10,010 K in profit during its latest quarter, and -81,390 K in sales during its previous quarter.
